A Study of Baricitinib in Healthy Japanese Participants

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to understand the relationship of 3 different dosage forms of baricitinib. This study will also explore the effect of food on how the body absorbs baricitinib. This study will last about 5 weeks, not including screening. Screening is required within 28 days prior to the date of first dosing.

Official Title
-----------------
Relative Bioavailability of the Baricitinib (LY3009104) Commercial Tablet Compared to the Phase 2 Tablets and the Effect of Food on the Bioavailability of the Commercial Tablet in Healthy Japanese Subjects

Conditions
-----------------
Healthy Participants

Intervention / Treatment
-----------------
* Drug: Baricitinib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Overtly healthy Japanese male and female (women not of child-bearing potential or after menopause), as determined by medical history and physical examination Have a body mass index (BMI) of 18.5 to 29.9 kilogram per square meter (kg/m^2) Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures Exclusion Criteria: Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study Have an abnormal blood pressure as determined by the investigator Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data Are women who are pregnant or lactating Have used or intend to use over-the-counter or prescription medication, including herbal medications, within 14 days prior to dosing and during the study. Have donated blood of more than 400 milliliter (mL) in the last 12 weeks (males) or in the last 16 weeks (females), or any blood donation (including apheresis) within the last 4 weeks, or total volume of blood donation within 12 months is 1200 mL (males) or 800 mL (females) at screening. Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females), or are unwilling to abide by alcohol restrictions Are participants who currently smoke more than 10 cigarettes per day (or equivalent in tobacco or nicotine products) or are unwilling to abide by smoking restrictions Have a current or recent history of a clinically significant bacterial, fungal, parasitic, viral (not including rhinopharyngitis), or mycobacterial infection Have an absolute neutrophil count (ANC) less than 2000 cells/microliter (µL)

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Baricitinib Test Treatment 1 (T1)<br>Single oral dose of 2 × 4 milligram (mg) baricitinib commercial formulation tablet fasted on Day 1 in one of five periods. | Drug: Baricitinib<br>* Administered orally<br>* Other names: LY3009104;|
| Experimental: Baricitinib Reference Treatment 1 (R1)<br>Single oral dose of 1 × 8 mg baricitinib Phase 2 tablet fasted on Day 1 in one of five periods. | Drug: Baricitinib<br>* Administered orally<br>* Other names: LY3009104;|
| Experimental: Baricitinib Test Treatment 2 (T2)<br>Single oral dose of 1 × 4 mg baricitinib commercial formulation tablet fasted on Day 1 in one of five periods. | Drug: Baricitinib<br>* Administered orally<br>* Other names: LY3009104;|
| Experimental: Baricitinib Reference Treatment 2 (R2)<br>Single oral dose of 1 × 4 mg baricitinib Phase 2 tablet fasted on Day 1 in one of five periods. | Drug: Baricitinib<br>* Administered orally<br>* Other names: LY3009104;|
| Experimental: Baricitinib Test Treatment 2 with Meal (T2F)<br>Single oral dose of 1 × 4 mg baricitinib commercial formulation tablet after food intake on Day 1 in one of five periods. | Drug: Baricitinib<br>* Administered orally<br>* Other names: LY3009104;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Baricitinib |  | Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, and 48 Hours Post-dose | 
| PK: Area Under the Concentration Versus Time Curve From Zero to Last Measurable Concentration (AUC[0-tlast]) of Baricitinib |  | Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, and 48 Hours Post-dose | 
| PK: Maximum Concentration (Cmax) of Baricitinib |  | Day 1: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, and 48 Hours Post-dose |